PTEN and large cell neuroendocrine carcinoma: LCNEC with RB1 mutations, as in SCLC, might best respond to an SCLC-like chemotherapy, whereas LCNEC tumors with PTEN loss and/or PI3KCA activating mutations might be optimally treated with platinum-based therapy [8, 9].